Therapeutic options in resistant aspergillosis are limited. Although more clinical experience with voriconazole is needed, data are sufficient to recommend its use in patients with invasive aspergillosis who have failed to respond to agents of choice (ie, conventional or liposomal amphotericin B, itraconazole). The drug may also be useful in patients with therapy-limiting toxicity associated with conventional regimens. Additional studies to assess the optimal dose, pharmacokinetics, and interaction potential of voriconazole are required. Data are too limited to suggest a role in candidiasis.
This drug should NOT be coded